MS
Publicaties op Oncologisch.com
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monothera...
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to Eerstelijns Pembro...
Orale taxaan ModraDoc006/r versus IV docetaxel bij mCRPC: fase II